In a patient with ulcerative colitis on budesonide (Cortiment) experiencing a flare, are CRP and white blood cell count elevated, and what laboratory changes indicate that budesonide is ineffective?

Laboratory Changes During UC Flare on Budesonide (Cortiment)

Yes, during a UC flare while on budesonide (Cortiment), you can see elevated CRP and WBC, though CRP elevation is less consistent in UC compared to other inflammatory conditions. 1

Expected Laboratory Findings During Active Flare

When experiencing a UC flare on budesonide, the following biomarker patterns indicate active inflammation:

Inflammatory Markers That May Be Elevated:

• Fecal calprotectin >150 mg/g - Most reliable marker for active inflammation 1
• CRP elevation - Can be elevated but is less sensitive in UC; approximately 40-50% of UC patients may not mount a significant CRP response even with active disease 2
• WBC elevation - May be elevated, particularly in more severe disease 2, 3
• Fecal lactoferrin - Elevated with active inflammation 1
• ESR elevation - Often elevated alongside WBC 3

Important Caveat About CRP in UC:

CRP is notably unreliable in UC - it may remain normal despite significant endoscopic inflammation. If CRP was elevated during your initial flare, then failure to normalize suggests ongoing inflammation, but a normal CRP does NOT rule out active disease 1.

Signs That Budesonide (Cortiment) Is Not Working

Clinical Indicators of Treatment Failure:

Persistent or worsening symptoms after 8 weeks of therapy indicate budesonide failure and necessitate treatment escalation 4, 5. Specifically look for:

• Continued bloody diarrhea
• Increased stool frequency
• Persistent abdominal pain
• Failure to achieve symptomatic improvement

Laboratory Indicators of Treatment Failure:

The AGA recommends combining biomarkers with symptoms to assess treatment response 1. If you have moderate-to-severe symptoms AND any of the following, budesonide is likely failing:

• Fecal calprotectin >150 mg/g (most reliable) 1
• Elevated fecal lactoferrin 1
• Elevated CRP (if it was elevated initially) 1
• Persistently elevated WBC and ESR 2, 3

Algorithmic Approach to Assessment:

1. If you have moderate-to-severe symptoms + elevated biomarkers (fecal calprotectin >150 mg/g, elevated CRP, or elevated fecal lactoferrin): This confirms active inflammation and indicates budesonide failure - proceed to treatment escalation without requiring endoscopy 1

2. If you have mild symptoms + elevated biomarkers: Perform endoscopy to confirm active disease before escalating therapy 1

3. If biomarkers are normal but symptoms persist: Consider endoscopy to differentiate inflammatory disease from functional symptoms 1

Predictors of Budesonide Non-Response

Real-world data shows that 46% of UC patients require transition from budesonide to prednisone due to inadequate response 4. Risk factors for budesonide failure include:

• Male sex (adjusted OR 2.96) 4
• Younger age at diagnosis (≤29 years) (adjusted OR 3.10) 4
• More extensive disease involvement

Practical Recommendations

Fecal calprotectin is your most reliable marker - it outperforms CRP and WBC for detecting active inflammation in UC 1, 2. If fecal calprotectin remains >150 mg/g after 8 weeks of budesonide with persistent symptoms, the medication is not working and you need to escalate to systemic corticosteroids or biologics.

Do not rely on CRP alone - up to 50% of UC patients with active endoscopic disease have normal CRP 1, 2. WBC elevation is similarly inconsistent and less specific than fecal markers.

The 8-week mark is critical - budesonide MMX is designed for 8-week induction therapy 5, 6. If you haven't achieved clinical and endoscopic remission by then, it's time to escalate treatment rather than continue ineffective therapy.